Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN

Anticancer Research

Volumn 26, Issue 2 B, 2006, Pages 1543-1556

  Branca, M ^a   Ciotti, M ^b   Giorgi, C ^a   Santini, D ^c   Di Bonito, L ^d   Costa, S ^c   Benedetto, A ^b   Bonifacio, D ^d   Di Bonito, P ^a   Paba, P ^b   Accardi, L ^a   Syrjanen S ^e   Favalli, C ^b   Syrjänen, Kari ^a,f  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e UNIVERSITY OF TURKU   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cervical cancer; CIN; HPV persistence; Matrix metalloproteinase 2; Oncogenic human papillomavirus; Prognosis; Tissue inhibitor of matrix metalloproteinase 2

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION RISK; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UTERINE CERVICAL NEOPLASMS;

EID: 33645831799     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Syrjänen K and Syrjänen S: Papillomavirus Infections in Human Pathology. J Wiley & Sons, Chichester, pp. 1-615, 2000.
2. Aubin F, Pretet JL and Mougin C (eds.): Papillomavirus Humains. Biologie et Pathologie Tumorale. Editions TEC & DOC, Paris, pp. 1-759, 2003.
3. Campo S (ed.): Papillomavirus Research: From Natural History to Vaccines and Beyond. Caister Academic Press, Norwich, UK, pp. 1-424, 2006.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ and Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
5. Cliffort GM, Gallus S, Herrero R, Munoz N, Snijders PJF, Vaccarella S, Anh PTH, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjose S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJLM and Franceschi S: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for research on cancer HPV prevalence surveys: pooled analysis. Lancet 366: 991-998, 2005.
6. von Knebel Doeberitz M: New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38: 2229-2242, 2002.
7. INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol 24: 118-124, 2005.
8. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M et al: Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78: 11451-11460, 2004.
9. INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 23: 354-365, 2004.
10. Branca M, Ciotti M, Santini D, Bonito LD, Benedetto A, Giorgi C, Paba P, Favalli C, Costa S, Agarossi A, Alderisio M and Syrjänen K: Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 122: 902-911, 2004.
11. Fehrman F and Laiminis LA: Human papillomaviruses: targeting differentiated epithelial cells for malignant transformation. Oncogene 22: 5201-5207, 2003.
12. Sorvari T, Sarnesto A and Syrjänen K: Type IV collagen in the basal membrane of human papillomavirus associated premalignant and malignant squamous cell lesions of the uterine cervix. Gynecol Obstet Invest 26: 324-331, 1988.
13. John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastases. Pathol Oncol Res 7: 14-23, 2001.
14. Zhai Y, Hotary KB, Nan B, Bosch FX, Munoz N, Weiss SJ and Cho KR: Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. Cancer Res 65: 6543-6550, 2005.
15. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
16. Crawford HC and Matrisian LM: Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 14: 234-245, 1994.
17. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS and Lopez-Otin C: Matrix metalloproteinases and tumour progression. Adv Exp Med Biol 532: 91-107, 2003.
18. Curran S and Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36: 425-431, 2000.
19. Ahmed MI, Salahy EE, Tawfiq H, Khalifa A and Hassan MM: Matrix metalloproteinase-2, squamous cell carcinoma antigen, and tissue polypeptide-specific antigen expression in Egyptian patients with cervical carcinoma: relationship with prognosis. Dis Markers 20: 333-343, 2004.
20. Stevenson WG, Brown PD, Onisto M, Levy AT and Liotta LA: Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 265: 13933-13938, 1990.
21. Murphy G and Docherty AJP: The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 7: 120-125, 1992.
22. Davidson B, Goldberg I, Kopolovic J, Lerner-Geva L, Gotlieb WH, Ben-Baruch G et al: MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma - a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gynecol Oncol 73: 372-382, 1999.
23. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, De Nictolis M and Biagini G: Microinvasive cervical carcinoma and cervical intraepithelial neoplasia: biologic significance and clinical implications of 72-kDa metalloproteinase immunostaining. Gynecol Oncol 61: 197-203, 1996.
24. Nair SA, Karunagaran D, Nair MB and Sudhakaran PR: Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol 129: 123-131, 2003.
25. Brummer O, Bohmer G, Hollwitz B, Flemming P, Petry KU and Kuhnle H: MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation - an immunohistochemical study. Gynecol Oncol 84: 222-227, 2002.
26. Talvensaari A, Apaja-Sarkkinen M, Hoyhtya M, Westerlund A, Puistola U and Turpeenniemi T: Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gynecol Oncol 72: 306-311, 1999.
27. Nuovo GJ: In situ detection of PCR-amplified metalloproteinase cDNAs, their inhibitors and human papillomavirus transcripts in cervical carcinoma cell lines. Int J Cancer 71: 1056-1060, 1997.
28. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Romanini C and Biagini G: Recurrence patterns in locally advanced cervical carcinoma: role of nodal status and 72-kDa metalloproteinase index. Gynecol Oncol 61: 83-89, 1996.
29. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Menso S, de Nictolis M, Romanini C and Biagini G: The role of Human papillomavirus DNA in cervical carcinoma and risk of lymph node metastases. Association with 72-kilodalton metalloproteinase immunostaining. Cancer 82: 886-892, 1998.
30. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, Romanini C and Biagini G: The 72-kDa metalloproteinase immunostaining in cervical carcinoma: relationship with lymph nodal involvement. Gynecol Oncol 60: 271-276, 1996.
31. Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Benedetto A, Paba P, Costa S, Bonifacio D, Di Bonito P, Accardi L, Favalli C and Syrjänen K: Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 59: 40-47, 2006.
32. Syrjänen KJ: Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 26: 118-124, 2005.
33. Branca M, Costa S, Mariani L, Piccione E, Sesti F, Agarossi A, di Carlo A, Galati M, Ciotti M, Paba P, Benedetto A, Giorgi C, Criscuolo A, Valieri M, Favalli C, Santini D, Alderisio M, De Nuzzo M, di Bonito L and Syrjänen K: Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study. Eur J Gynaecol Oncol 25: 689-698, 2004.
34. Costa S, Terzano P, Santini D, Panetta A, Martoni A, Bovicelli A, De Nuzzo M, Lipponen P, Erzen M, Syrjänen S and Syrjänen K: CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 80: 67-73, 2001.
35. Costa S, Terzano P, Santini D, Ceccarelli C, Martoni A, Angelelli B, Panetta A, Bovicelli A, Cristiani P, Lipponen P, Erzen M, Syrjänen S and Syrjänen K: Neoadjuvant chemotherapy in cervical carcinoma: regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 116: 729-737, 2001.
36. Costa S, Simone PD, Venturoli S, Cricca M, Zerbini ML, Musiani M, Terzano P, Santini D, Cristiani P, Syrjänen S and Syrjänen K: Factors predicting human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. Gynecol Oncol 90: 358-365, 2003.
37. Bauer HM, Gréer CE and Manos M: Determination of genital human papillomavirus infection using consensus PCR. In: Diagnostic Molecular Pathology: A Practical Approach. Herrington CS and McGee JOD (eds.). Oxford University Press, Oxford, pp. 132-152, 1992.
38. Karlsen F, Kalantari M, Jenkins A, Pettersen E, Kristensen G, Holm R, Johansson B and Hagmar B: Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34: 2095-2100, 1996.
39. Kleter B, van Doorn LJ, Scrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M and Quint W: Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 37: 2508-2517, 1999.
40. Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Costa S, Benedetto A, Casolati EA, Favalli C, Paba P, Di Bonito P, Mariani L, Syrjänen S, Bonifacio D, Accardi L, Zanconati F and Syrjänen K: Aberrant expression of a novel inhibitor of apoptosis (Survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer. Am J Clin Pathol 124: 113-121, 2005.
41. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, Benedetto A, Bonifacio D, Di Bonito P, Paba P, Accardi L, Mariani L, Ruutu M, Favalli C and Syrjänen K: Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. J Clin Pathol, 2006. In press.
42. Gaiotto MA, Focchi J, Ribalta JL, Stavale JN, Baracat EC, Lima GR et al: Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cell cervical carcinoma. Am J Obstet Gynecol 190: 1278-1282, 2004.
43. Malina R, Motoyama S, Hamana S and Maruo T: Laminin-5 gamma2 chain and matrix metalloproteinase-2 expression in the neoplastic changes of uterine cervical squamous epithelium. Kobe J Med Sci 50: 123-130, 2004.
44. Arguello-Ramirez J, Perez-Cardenas E, Delgado-Chavez R, Solorza-Luna G, Villa-Trevino S and Arenas-Huertero F: Matrix metalloproteinases-2, -3, and -9 secreted by explants of benign and malignant lesions of the uterine cervix. Int J Gynecol Cancer 14: 333-340, 2004.
45. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC and Lin RH: A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 61: 237-242, 2001.
46. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S and Ito A: Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 92: 47-56, 2004.
47. Moser PL, Kieback DG, Hefler L, Tempfer C, Neunteufel W and Gitsch G: Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage IB cervical cancer. Anticancer Res 19: 4391-4393, 1999.
48. Zhou CY, Yao JF and Chen XD: Expression of matrix metalloproteinase-2, 9 and their inhibitor-TIMP 1,2 in human squamous cell carcinoma of uterine cervix. Ai Zheng 21: 735-739, 2002.
49. Ueda M, Terai Y, Yamashita Y, Kumagai K, Ueki K, Yamaguchi H et al: Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int J Cancer 98: 335-343, 2002.
50. Tamakoshi K, Kikkawa F, Nawa A, Ishikawa H, Mizuno K, Tamakoshi A, Yamagata S, Suganuma N and Tomoda Y: Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. Cancer 76: 2565-2571, 1995.
51. Nuovo GJ, MacConnell PB, Simsir A, Valea F and French DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 55: 267-275, 1995.
52. Mitra A, Chakrabarti J, Banerji A and Chatterjee A: Binding of alpha2 monoclonal antibody to human cervical tumor cell (SiHa) surface alpha2beta1 integrin modulates MMP-2 activity. Gynecol Oncol 94: 33-39, 2004.
53. Chattopadhyay N, Mitra A, Frei E and Chatterjee A: Human cervical tumor cell (SiHa) surface alphavbeta3 integrin receptor has associated matrix metalloproteinase (MMP-2) activity. J Cancer Res Clin Oncol 127: 653-658, 2001.
54. Van Trappen PO, Ryan A, Carroll M, Lecoeur C, Goff L, Gyselman VG et al: A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer 87: 537-544, 2002.
55. Ueda M, Terai Y, Kumagai K, Ueki K, Kanemura M and Ueki M: Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells. Int J Cancer 91: 778-782, 2001.
56. Ivanova T, Vinokurova S, Petrenko A, Eshilev E, Solovyova N, Kisseljov F et al: Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer. Int J Cancer 108: 882-886, 2004.
57. Iwasaki M, Nishikawa A, Fujimoto T, Akutagawa N, Manase K, Endo T et al: Anti-invasive effect of MMI-166, a new selective matrix metalloproteinase inhibitor, in cervical carcinoma cell lines. Gynecol Oncol 85: 103-107, 2002.